Literature DB >> 22227663

The value of HPV vaccination.

.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22227663     DOI： 10.1038/nm0112-28

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

1.  FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  Assessing incidence and economic burden of genital warts with data from a US commercially insured population.

Authors:  Tracey Hoy; Puneet K Singhal; Vincent J Willey; Ralph P Insinga
Journal:  Curr Med Res Opin       Date:  2009-10       Impact factor: 2.580

3.  Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

Authors:  Julia M L Brotherton; Masha Fridman; Cathryn L May; Genevieve Chappell; A Marion Saville; Dorota M Gertig
Journal:  Lancet       Date:  2011-06-18       Impact factor: 79.321

4.  Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

Authors:  Julianne Gee; Allison Naleway; Irene Shui; James Baggs; Ruihua Yin; Rong Li; Martin Kulldorff; Edwin Lewis; Bruce Fireman; Matthew F Daley; Nicola P Klein; Eric S Weintraub
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

5.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Authors:  Susanne K Kjær; Kirsten Frederiksen; Christian Munk; Thomas Iftner
Journal:  J Natl Cancer Inst       Date:  2010-09-14       Impact factor: 13.506

6.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Authors:  Nubia Muñoz; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricía J Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Warner K Huh; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret K James; Teresa M Hesley; Eliav Barr; Richard M Haupt
Journal:  J Natl Cancer Inst       Date:  2010-02-05       Impact factor: 13.506

7.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Authors:  Darron R Brown; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Eng Hseon Tay; Patricía Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret James; Teresa M Hesley; Eliav Barr
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

8.  Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

Authors:  B Romanowski; P Colares de Borba; P S Naud; C M Roteli-Martins; N S De Carvalho; J C Teixeira; F Aoki; B Ramjattan; R M Shier; R Somani; S Barbier; M M Blatter; C Chambers; D Ferris; S A Gall; F A Guerra; D M Harper; J A Hedrick; D C Henry; A P Korn; R Kroll; A-B Moscicki; W D Rosenfeld; B J Sullivan; C S Thoming; S K Tyring; C M Wheeler; G Dubin; A Schuind; T Zahaf; Mary Greenacre; An Sgriobhadair
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

Review 9.  Human papillomavirus infection and the primary and secondary prevention of cervical cancer.

Authors:  Douglas R Lowy; Diane Solomon; Allan Hildesheim; John T Schiller; Mark Schiffman
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Authors:  Sue J Goldie; Meredith O'Shea; Nicole Gastineau Campos; Mireia Diaz; Steven Sweet; Sun-Young Kim
Journal:  Vaccine       Date:  2008-05-15       Impact factor: 3.641
View more
  2 in total

1.  Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Authors:  Kirill Kalnin; Timothy Tibbitts; Yanhua Yan; Svetlana Stegalkina; Lihua Shen; Victor Costa; Robert Sabharwal; Stephen F Anderson; Patricia M Day; Neil Christensen; John T Schiller; Subhashini Jagu; Richard B S Roden; Jeffrey Almond; Harold Kleanthous
Journal:  Vaccine       Date:  2014-04-26       Impact factor: 3.641

2.  Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.

Authors:  K Kavanagh; K G J Pollock; A Potts; J Love; K Cuschieri; H Cubie; C Robertson; M Donaghy
Journal:  Br J Cancer       Date:  2014-04-15       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.